Free shipping on all orders over $ 500

PF-3758309

Cat. No. M3110
PF-3758309 Structure
Synonym:

PF-03758309

Size Price Availability Quantity
10mM*1mL in DMSO USD 65  USD65 In stock
5mg USD 60  USD60 In stock
10mg USD 90  USD90 In stock
25mg USD 180  USD180 In stock
50mg USD 280  USD280 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

PF-3758309 is an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC(50) = 1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC(50) = 4.7 +/- 3 nM). PF-3758309 also inhibits cellular proliferation (IC50 = 20 nM) and anchorage-independent growth (IC50 = 27 nM) of A549 cells. PF-3758309 blocks the growth of multiple human tumor xenografts, with a plasma EC50 value of 0.4 nM in the most sensitive model. In tumor models, PF-3758309 inhibits PAK4-dependent pathways in proteomic studies and regulates functional activities related to cell proliferation and survival.

Protocol (for reference only)
Cell Experiment
Cell lines HEK293T, HCT116, and SKOV3 cells
Preparation method Using a panel of cancer cell lines test the potency of PF-3758309. On day 1, plating cells on 384-well plates. On day 2, adding compounds to the cell culture. Incubating the cells with the compound for 3 days. On day 5, aspirating all media from the wells. Dose-dependent effects of PF-3758309 on cell proliferation are quantified via the CellTiter-Glo Luminescent Cell Viability Assay(a,b,c), which is a homogeneous method of determining the number of viable cells in culture based on quantitation of the ATP present, an indicator of metabolically active cells. Proliferation data displayed for HEK293T, HCT116, and SKOV3 cells are measured using the Cyquant NF assay as specified by the manufacturer. Briefly, 24 h after seeding on 384-well plates, cells are treated with vehicle or PF-3758309, Dasatinib, or the positive control, Bleomycin (60 mU/ mL).After drug treatment for 72 hours, cell proliferation is measured. Results for each drug are normalized to vehicle control and expressed as a percentage of maximum assay inhibition relative to Bleomycin. Error bars represent the SD from at least three experiments
Concentrations ~1 μM
Incubation time 72 hours
Animal Experiment
Animal models Xenograft tumors in nude mice
Formulation 0.5% methylcellulose
Dosages 7.5-30 mg/kg BID
Administration p.o.
Chemical Information
Molecular Weight 490.62
Formula C25H30N8OS
CAS Number 898044-15-0
Solubility (25°C) DMSO 10 mM
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Zhao ZS, et al. F1000 Biol Rep. Do PAKs make good drug targets?

[2] Murray BW, et al. Proc Natl Acad Sci U S A. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.

Related PAK Products
st-Ht31

st-Ht31 is a membrane-permeable peptide inhibitor of protein kinase A (PKA) anchoring.

AZA197

AZA197 is a selective small molecule inhibitor of Cdc42.AZA197 suppresses colon cancer cell proliferation, cell migration, invasion and increases apoptosis by down-regulating the PAK1 and ERK signaling pathways in vitro.

ZMF-23

ZMF-23 is a PAK1/HDAC6 dual inhibitor.

PF-3758309 dihydrochloride

PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation.

AZ13705339 hemihydrate 

AZ13705339 hemihydrate is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 hemihydrate has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 hemihydrate can be used in the research of cancers.

  Catalog
Abmole Inhibitor Catalog




Keywords: PF-3758309, PF-03758309 supplier, PAK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.